References
- Magnus EM. Folate activity in serum and red cells of patients with cancer. Cancer Res 1967; 27 (3): 490–497.
- Clamon GH, Feld R, Evans WK et al. Serum folate and vitamin B12 levels in patients with small cell lung cancer. Cancer 1984; 53 (2): 306-310.
- Pinedo HM, Peters CF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6 (10): 1653–1664.
- Thirion P, Michiels S, Pignon JP et al. Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22 (18): 3766–3775.
- Branda RF, Nigels E, Lafayette AR, Hacker M. Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats. Blood 1998; 92 (7): 2471–2476.
- Raghunathan K, Schmitz JC, Priest DG. Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice. Biochem Pharmacol 1997; 53 (8): 1197–1202.
- Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and total homocys-teine determinations for diagnosing cobalamin and folate defi-ciencies. Am J Med 1994; 96 (3): 239–246.
- Neoptolemos JP, Stocken DD, Friess H et al; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pan-creatic cancer. N Engl J Med 2004; 350 (12): 1200–1210.
- Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345 (10): 725–730.
- Cunningham D, Allum WH, Stenning SP et al, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355 (1): 11–20.
- Oken MM, Creech RH, Tormey DC et al. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655.
- http://www.ctep.nci.nih.gov
- Tzortzatou F. Reversibility of the toxicity of methotrex-ate by dihydrofolate in mice. Clin Exp Pharmacol Physiol 1979; 6 (5): 581–583.
- Bertino JR, Levitt M, McCullough JL, Chabner B. New approaches to chemotherapy with folate antagonists: use of leucovorin “rescue” and enzymic folate depletion. Ann N Y Acad Sci 1971; 186: 486–495.
- Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol. 1999; 17 (5): 1589–94.
- Calvert H. Folate status and the safety profile of antifo-lates. Semin Oncol 2002; 29 (2 Suppl 5): 3-7.
- Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1 (7): 545–552.
- Niyikiza C, Hanauske AR, Rusthoven JJ et al. Pemetrexed safety and dosing strategy. Semin Oncol 2002; 29 (6 Suppl 18): 24-29.
- Sharma R, Rivory L, Beale P et al. A phase II study of fixed-dose capecitabine and assessment of predictors of toxici-ty in patients with advanced/metastatic colorectal cancer. Br J Cancer 2006; 94 (7): 964–968.
- [No authors listed] Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998; 16 (11): 3537-3541.